A 83-01
Based on 134 publication(s) in Google Scholar
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.41%
- CAS 番号: 909910-43-6
- 分子式: C25H19N5S
- 分子量:421.52
-
保管条件:
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 A 83-01
More- Nature. 2026 Jun 17. [Abstract]
- Science. 2020 Dec 4;370(6521):eaay2002. [Abstract]
- Cancer Cell. 2026 May 21:S1535-6108(26)00220-5.
- Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
- Cell. 2024 Nov 14;187(23):6566-6583.e22. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Nat Photonics. 2025 Jul 10.
- Nat Methods. 2025 Mar;22(3):510-519. [Abstract]
- Nat Genet. 2024 Feb;56(2):294-305. [Abstract]
- Cancer Commun (Lond). 2025 Nov 10. [Abstract]
- Cell Stem Cell. 2026 Mar 5;33(3):502-516.e7. [Abstract]
- Cell Stem Cell. 2025 Dec 23:S1934-5909(25)00436-9. [Abstract]
- Cell Stem Cell. 2025 Mar 6;32(3):391-408.e11. [Abstract]
- Cell Stem Cell. 2025 Mar 6;32(3):409-425.e8. [Abstract]
- Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10. [Abstract]
- Nat Cell Biol. 2026 Apr;28(4):797-811. [Abstract]
- Nat Cell Biol. 2022 Jun;24(6):858-871. [Abstract]
- Adv Funct Mater. 2026 Apr 3.
- Cancer Res. 2026 May 28:10.1158/0008-5472.CAN-25-3935. [Abstract]
- Cancer Res. 2026 Mar 5. [Abstract]
- Cancer Res. 2025 Nov 6. [Abstract]
- Cancer Res. 2025 Oct 9. [Abstract]
- Cancer Res. 2025 May 2;85(9):1628-1643. [Abstract]
- Nat Protoc. 2023 May;18(5):1584-1620. [Abstract]
- Nat Commun. 2025 Aug 26;16(1):7954. [Abstract]
- Nat Commun. 2025 Jul 17;16(1):6575. [Abstract]
- Nat Commun. 2022 Sep 6;13(1):5237. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Adv Sci (Weinh). 2025 Nov 3:e09151. [Abstract]
- Adv Sci (Weinh). 2024 Nov 25:e2401227. [Abstract]
- Adv Sci (Weinh). 2024 Dec 4:e2408852. [Abstract]
- Adv Sci (Weinh). 2024 Nov;11(43):e2402299. [Abstract]
- Adv Sci (Weinh). 2022 Sep;9(26):e2202505. [Abstract]
- Theranostics. 2024 Jan 1;14(3):1049-1064. [Abstract]
- Theranostics. 2021 Mar 14;11(11):5539-5552. [Abstract]
- Sci Adv. 2025 Sep 5;11(36):eadz0808. [Abstract]
- Sci Adv. 2025 May 9;11(19):eadr3173. [Abstract]
- Sci Adv. 2023 Dec 22;9(51):eadi5683. [Abstract]
- Sci Adv. 2021 Apr 14;7(16):eabb2213. [Abstract]
- Redox Biol. 2025 Jun:83:103615. [Abstract]
- Engineering. 2025 Aug 27.
- Genome Med. 2024 Apr 24;16(1):60. [Abstract]
- Cell Rep Med. 2026 Mar 17;7(3):102644. [Abstract]
- Cell Rep Med. 2026 Feb 17;7(2):102622. [Abstract]
- Cell Rep Med. 2025 Feb 18;6(2):101966. [Abstract]
- Biomater Res. 2025 Dec 9:29:0293. [Abstract]
- Cell Death Dis. 2025 Aug 30;16(1):660. [Abstract]
- Cell Death Dis. 2024 Aug 3;15(8):559. [Abstract]
- Genes Dis. 2025 May 2;12(6):101665. [Abstract]
- Nano Res. 03 August 2022.
- J Pharm Anal. 2024 Mar;14(3):335-347. [Abstract]
- Int J Biol Macromol. 2025 Dec 12;338(Pt 1):149672. [Abstract]
- Acta Pharmacol Sin. 2025 May;46(5):1404-1418. [Abstract]
- Acta Pharmacol Sin. 2024 Dec;45(12):2611-2624. [Abstract]
- Biofabrication. 2025 Aug 12;17(4). [Abstract]
- Biomed Pharmacother. 2025 May 1:187:118094. [Abstract]
- J Transl Med. 2021 Dec 7;19(1):497. [Abstract]
- Stem Cell Res Ther. 2025 Oct 8;16(1):547. [Abstract]
- Stem Cell Res Ther. 2025 Mar 11;16(1):132. [Abstract]
- Stem Cell Res Ther. 2024 Dec 18;15(1):478. [Abstract]
- Cell Rep. 2023 May 23;42(6):112546. [Abstract]
- Cell Rep. 2022 Jul 12;40(2):111053. [Abstract]
- Br J Cancer. 2026 Jun;134(12):1744-1753. [Abstract]
- Clin Transl Med. 2025 Dec;15(12):e70541. [Abstract]
- Br J Cancer. 2025 Aug 26. [Abstract]
- Br J Cancer. 2025 Jan;132(1):126-136. [Abstract]
- Int J Radiat Oncol Biol Phys. 2024 Mar 1;118(3):817-828. [Abstract]
- Cell Prolif. 2024 Jun;57(6):e13599. [Abstract]
- Cell Prolif. 2023 Jan;56(1):e13320. [Abstract]
- Cells. 2024 Aug 31.
- Commun Biol. 2026 Jan 15;9(1):266. [Abstract]
- Commun Biol. 2025 Jul 4;8(1):995. [Abstract]
- Respir Res. 2026 Feb 28;27(1):109. [Abstract]
- Biomed Signal Process Control. 2026 Feb 26.
- Int J Mol Sci. 2025 May 31;26(11):5306. [Abstract]
- Int J Mol Sci. 2023 Dec 29;25(1):477. [Abstract]
- Int J Cancer. 2024 May 15;154(10):1814-1827. [Abstract]
- Am J Physiol Cell Physiol. 2023 Jul 1;325(1):C344-C361. [Abstract]
- Mol Oncol. 2024 Mar;18(3):547-561. [Abstract]
- FASEB J. 2023 Dec;37(12):e23279. [Abstract]
- FASEB J. 2023 Jul;37(7):e22983. [Abstract]
- FASEB J. 2020 Aug;34(8):11185-11199. [Abstract]
- iScience. 2026 Jan 27;29(2):114786. [Abstract]
- iScience. 2025 Oct 17;28(11):113801. [Abstract]
- iScience. 2025 Apr 3;28(5):112344. [Abstract]
- iScience. 2025 Jan 17;28(2):111827. [Abstract]
- Gynecol Oncol. 2019 Jun;153(3):639-650. [Abstract]
- Sci Rep. 2025 Mar 12;15(1):8531. [Abstract]
- J Biol Chem. 2022 Sep;298(9):102374. [Abstract]
- Cell Signal. 2025 Jun 17:111946. [Abstract]
- Front Med. 2021 Sep 23;8:746298. [Abstract]
- Stem Cells Int. 2025 Jul 11:2025:5105796. [Abstract]
- Hum Cell. 2024 Nov 4;38(1):13. [Abstract]
- Biol Reprod. 2025 May 13:ioaf108. [Abstract]
- Reprod Toxicol. 2024 Jan:123:108522. [Abstract]
- In Vitro Model. 2025 Mar 5;4(1):31-44. [Abstract]
- Cancer Biomark. 2025 Oct;42(10):18758592251390145. [Abstract]
- STAR Protoc. 2026 Feb 19;7(1):104381. [Abstract]
- J Vis Exp. 2025 Jan 31:(215). [Abstract]
- bioRxiv. 2026 May 4.
- medRxiv. 2026 Mar 7.
- Res Sq. 2026 Mar 4.
- Res Sq. 2026 Jan 15.
- bioRxiv. 2026 Jan 23.
- bioRxiv. 2025 Dec 24.
- bioRxiv. 2025 Dec 26.
- University of California. 2025.
- bioRxiv. 2025 Aug 30.
- bioRxiv. 2025 Aug 8:2025.08.08.669417. [Abstract]
- Res Sq. 2025 Jul 14.
- SSRN. 2025 Jun 3.
- Methods Mol Biol. 2025 May 17. [Abstract]
- SSRN. 2025 May 27.
- Methods Mol Biol. 2025 May 22. [Abstract]
- bioRxiv. 2025 May 12.
- Patent. US20250129329A1.
- bioRxiv. 2025 April 30.
- bioRxiv. 2025 April 14.
- bioRxiv. 2025 January 28.
- Patent. US20240319170A1
- Patent. US20240344020A1
- Patent. US20240344020A1.
- bioRxiv. 2024 November 18.
- bioRxiv. 2024 August 11.
- bioRxiv. 2024 July 22.
- SSRN. 2024 May 30.
- SSRN. 2024 May 23.
- bioRxiv. 2024 Feb 27.
- Methods Mol Biol. 2024:2767:1-18. [Abstract]
- Patent. US20220389379A1.
- Methods Mol Biol. 2024:2767:53-62. [Abstract]
- Methods Mol Biol. 2024:2767:43-52. [Abstract]
- Methods Mol Biol. 2022:2454:811-827. [Abstract]
- Research Square Preprint. 2021 Jan.
Customer Validation & Images
-
RT-PCR
-
IF
-
Cell Proliferation/Viability Assay
-
IF
-
WB
生物活性
|
ALK5 12 nM (IC50) |
ALK4 45 nM (IC50) |
ALK7 7.5 nM (IC50) |
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, reduces the level of ALK-5-induced transcription with an IC50 of 12 nM in Mv1Lu cells, also blocks the ALK4-TD and ALK7-TD induced transcription with IC50s of 45 nM and 7.5 nM in R4-2 cells, and weakly suppresses that induced by constitutively active ALK-6, ALK-2, ALK-3, and ALK-1. A 83-01 (0.03-10 μM) potently prevents the growth-inhibitory effects of TGF-β, and completely inhibits the effect at 3 μM. A 83-01 (1-10 μM) inhibits TGF-β-induced Smad activation in HaCaT cells[1]. A 83-01 (1 μM) decreases cell motility, adhesion and invasion increased by TGF-β1 in HM-1 cells, but does not change cell proliferation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 909910-43-6
-
性状 Solid
-
分子量 421.52
-
分子式 C25H19N5S
-
Color Off-white to light yellow
-
SMILES
S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5
-
別名
909910-43-6
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (134)
-
Journal Impact Factor
-
Most Recent
-
-
Science
2020 Dec 4;370(6521):eaay2002. PMID: 33093214 -
-
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606 -
Cell
2024 Nov 14;187(23):6566-6583.e22. PMID: 39332412 -
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
-
Nat Methods
Challenging the Astral mass analyzer to quantify up to 5,300 proteins per single cell at unseen accuracy to uncover cellular heterogeneity. [Abstract]2025 Mar;22(3):510-519. PMID: 39820751 -
Nat Genet
Single-nucleus multi-omic profiling of human placental syncytiotrophoblasts identifies cellular trajectories during pregnancy. [Abstract]2024 Feb;56(2):294-305. PMID: 38267607
A 83-01 purchased from MedChemExpress. Usage Cited in: Nat Genet. 2024 Feb;56(2):294-305. [Abstract]
Trophoblast organoids constructed from hTSCs-BL. Trophoblast markers: CDH1 and hCG. Briefly, hTSCs were cultured in hTSCs medium (DMEM/F12 supplemented with 0.1 mM 2-mercaptoethanol, 0.2% FBS, 0.5% Penicillin–Streptomycin, 0.3% BSA, 1% ITS-X supplement, 1.5 μg/ml L-ascorbicacid, 50 ng/mL Epidermal Growth Factor (EGF)(MedChemExpress), 2 μM CHIR99021 (MedChemExpress), 0.5 μM A83-01 (MedChemExpress), 1 μM SB431542 (MedChemExpress), 0.8 mM Valproic acid and 5 μM Y27632 (MedChemExpress).
-
Cancer Commun (Lond)
Unfolded protein response kinase PERK supports survival and metastasis of circulating tumor cell clusters via SAM synthesis and H3K4me3-dependent PDGFB signaling. [Abstract]2025 Nov 10. PMID: 41212905 -
Cell Stem Cell
VIPR1 acts as an enteric neural checkpoint that suppresses intestinal stem cell-driven epithelial regeneration and exacerbates colitis. [Abstract]2026 Mar 5;33(3):502-516.e7. PMID: 41734764 -
Cell Stem Cell
2025 Dec 23:S1934-5909(25)00436-9. PMID: 41443195 -
Cell Stem Cell
Mouse totipotent blastomere-like cells model embryogenesis from zygotic genome activation to post implantation. [Abstract]2025 Mar 6;32(3):391-408.e11. PMID: 39826539 -
Cell Stem Cell
Modeling early gastrulation in human blastoids with DNA methylation patterns of natural blastocysts. [Abstract]2025 Mar 6;32(3):409-425.e8. PMID: 39814012 -
Cell Stem Cell
2022 Sep 1;29(9):1346-1365.e10. PMID: 36055191 -
Nat Cell Biol
The lncRNA DAMER selectively guides m6A-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer. [Abstract]2026 Apr;28(4):797-811. PMID: 41792266 -
Nat Cell Biol
Integrated multi-omics reveal polycomb repressive complex 2 restricts human trophoblast induction. [Abstract]2022 Jun;24(6):858-871. PMID: 35697783 -
-
Cancer Res
ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis through Symbiotic Adhesion and Reverse Migration. [Abstract]2026 May 28:10.1158/0008-5472.CAN-25-3935. PMID: 42207963 -
Cancer Res
2026 Mar 5. PMID: 41784633 -
Cancer Res
USP20-Driven Cholesterol Metabolism Links Inflammatory Signaling to Malignancy and Stromal Co-evolution in Pancreatic Cancer. [Abstract]2025 Nov 6. PMID: 41196022 -
Cancer Res
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer. [Abstract]2025 Oct 9. PMID: 41066596 -
Cancer Res
The Glycosyltransferase XYLT1 Activates NF-κB Signaling to Promote Metastasis of Early-Stage Lung Adenocarcinoma. [Abstract]2025 May 2;85(9):1628-1643. PMID: 39992715
A 83-01 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 May 2;85(9):1628-1643. [Abstract]
A83-01 (10 μM; 12 h) suppresses the expression of XYLT1 in bone-metastatic A549 cells.
-
Nat Protoc
2023 May;18(5):1584-1620. PMID: 36792779 -
Nat Commun
Helicobacter hepaticus promotes hepatic steatosis through CdtB-induced mitochondrial stress and lipid metabolism reprogramming. [Abstract]2025 Aug 26;16(1):7954. PMID: 40858606 -
Nat Commun
Cellular crosstalk mediated by TGF-β drives epithelial-mesenchymal transition in patient-derived multi-compartment biliary organoids. [Abstract]2025 Jul 17;16(1):6575. PMID: 40675983 -
Nat Commun
PIM1 promotes hepatic conversion by suppressing reprogramming-induced ferroptosis and cell cycle arrest. [Abstract]2022 Sep 6;13(1):5237. PMID: 36068222 -
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334 -
Adv Sci (Weinh)
Depletion of Sorcs3 Activates Totipotency in Mouse Embryonic Stem Cells by Modulating Key Signaling Pathways. [Abstract]2025 Nov 3:e09151. PMID: 41178446 -
Adv Sci (Weinh)
H. Pylori-Facilitated TERT/Wnt/β-Catenin Triggers Spasmolytic Polypeptide-Expressing Metaplasia and Oxyntic Atrophy. [Abstract]2024 Nov 25:e2401227. PMID: 39587848 -
Adv Sci (Weinh)
2024 Dec 4:e2408852. PMID: 39630006 -
Adv Sci (Weinh)
Embryo-Derived Cathepsin B Promotes Implantation and Decidualization by Activating Pyroptosis. [Abstract]2024 Nov;11(43):e2402299. PMID: 39316370 -
Adv Sci (Weinh)
Near-Infrared-Responded High Sensitivity Nanoprobe for Steady and Visualized Detection of Albumin in Hepatic Organoids and Mouse Liver. [Abstract]2022 Sep;9(26):e2202505. PMID: 35853243 -
Theranostics
Keratinocyte-to-macrophage communication exacerbate psoriasiform dermatitis via LRG1-enriched extracellular vesicles. [Abstract]2024 Jan 1;14(3):1049-1064. PMID: 38250043 -
Theranostics
The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction. [Abstract]2021 Mar 14;11(11):5539-5552. PMID: 33859762 -
Sci Adv
2025 Sep 5;11(36):eadz0808. PMID: 40911681 -
Sci Adv
Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m6A modification in triple-negative breast cancer. [Abstract]2025 May 9;11(19):eadr3173. PMID: 40344056 -
Sci Adv
Haploid-genetic screening of trophectoderm specification identifies Dyrk1a as a repressor of totipotent-like status. [Abstract]2023 Dec 22;9(51):eadi5683. PMID: 38117886 -
Sci Adv
Chemical conversion of human epidermal stem cells into intestinal goblet cells for modeling mucus-microbe interaction and therapy. [Abstract]2021 Apr 14;7(16):eabb2213. PMID: 33853767 -
Redox Biol
GPX4 deficiency-induced ferroptosis drives endometrial epithelial fibrosis in polycystic ovary syndrome. [Abstract]2025 Jun:83:103615. PMID: 40253746 -
-
Genome Med
Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors. [Abstract]2024 Apr 24;16(1):60. PMID: 38658971
A 83-01 purchased from MedChemExpress. Usage Cited in: Genome Med. 2024 Apr 24;16(1):60. [Abstract]
Cell viability assessment in the AtT20 cell line treated with Activin A (10 ng/ml) in the presence or absence of SB-505124 (1 μM), A 83–01 (1 μM; 24-96 h), or follistatin (100 ng/ml). K Cell viability analysis in AtT20 cell line with shEV-GFP or shAcvr1b treated with Activin A (10 ng/ml).
-
Cell Rep Med
Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. [Abstract]2026 Mar 17;7(3):102644. PMID: 41763214 -
Cell Rep Med
A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma. [Abstract]2026 Feb 17;7(2):102622. PMID: 41707653 -
Cell Rep Med
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. [Abstract]2025 Feb 18;6(2):101966. PMID: 39970873 -
Biomater Res
2025 Dec 9:29:0293. PMID: 41376821 -
Cell Death Dis
Targeting DDX3X suppresses progression of KRAS-driven lung cancer by disrupting antioxidative homeostasis and inducing ferroptosis. [Abstract]2025 Aug 30;16(1):660. PMID: 40885716 -
Cell Death Dis
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators. [Abstract]2024 Aug 3;15(8):559. PMID: 39097593 -
Genes Dis
Unraveling the role of the WIPF1/ACTN4 complex in podosome formation of human placental EVTs: Insights into recurrent spontaneous abortion. [Abstract]2025 May 2;12(6):101665. PMID: 40821124 -
-
J Pharm Anal
Hapln1 promotes dedifferentiation and proliferation of iPSC-derived cardiomyocytes by promoting versican-based GDF11 trapping. [Abstract]2024 Mar;14(3):335-347. PMID: 38618242 -
Int J Biol Macromol
Downregulation of the biological macromolecule Spondin-2 disrupts maternal-fetal immune tolerance and trophoblast invasion, driving unexplained recurrent pregnancy loss. [Abstract]2025 Dec 12;338(Pt 1):149672. PMID: 41391791 -
Acta Pharmacol Sin
Organoid modeling identifies USP3-AS1 as a novel promoter in colorectal cancer liver metastasis through increasing glucose-driven histone lactylation. [Abstract]2025 May;46(5):1404-1418. PMID: 39837984 -
Acta Pharmacol Sin
G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome. [Abstract]2024 Dec;45(12):2611-2624. PMID: 39054339 -
Biofabrication
Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy. [Abstract]2025 Aug 12;17(4). PMID: 40791084 -
Biomed Pharmacother
Transforming growth factor-β receptor I kinase plays a crucial role in oligodendrocyte regeneration after demyelination. [Abstract]2025 May 1:187:118094. PMID: 40315672 -
J Transl Med
Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis. [Abstract]2021 Dec 7;19(1):497. PMID: 34876143 -
Stem Cell Res Ther
Generation of equine induced pluripotent stem cells from cells of embryonic, perinatal and adult tissues. [Abstract]2025 Oct 8;16(1):547. PMID: 41063189 -
Stem Cell Res Ther
Modeling of lung organoid-based fibrosis for testing the sensitivity of anti-fibrotic drugs. [Abstract]2025 Mar 11;16(1):132. PMID: 40069846 -
Stem Cell Res Ther
Transcriptomic and proteomic sequencing unveils the role of vitamin D and metabolic flux shifts in the induction of human hepatic organoids. [Abstract]2024 Dec 18;15(1):478. PMID: 39696644 -
Cell Rep
2023 May 23;42(6):112546. PMID: 37224015 -
Cell Rep
Mesenchymal-epithelial interaction regulates gastrointestinal tract development in mouse embryos. [Abstract]2022 Jul 12;40(2):111053. PMID: 35830795 -
Br J Cancer
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial. [Abstract]2026 Jun;134(12):1744-1753. PMID: 41946829 -
Clin Transl Med
Single-cell transcriptome analyses reveal disturbed decidual microenvironment in women of advanced maternal age. [Abstract]2025 Dec;15(12):e70541. PMID: 41407538 -
Br J Cancer
2025 Aug 26. PMID: 40858831 -
Br J Cancer
2025 Jan;132(1):126-136. PMID: 39592739 -
Int J Radiat Oncol Biol Phys
2024 Mar 1;118(3):817-828. PMID: 37820768 -
Cell Prolif
ISRIB facilitates the co-culture of human trophoblast stem cells and embryonic stem cells. [Abstract]2024 Jun;57(6):e13599. PMID: 38217296 -
Cell Prolif
Novel strategy for primary epithelial cell isolation: Combination of hyaluronidase and collagenase I. [Abstract]2023 Jan;56(1):e13320. PMID: 35920005 -
-
Commun Biol
Epigenetic and metabolic rewiring in metastatic pheochromocytomas and paragangliomas driven by SDHB mutations. [Abstract]2026 Jan 15;9(1):266. PMID: 41540233 -
Commun Biol
Endometrial stromal Menin supports endometrial receptivity by maintaining homeostasis of WNT signaling pathway through H3K4me3 during WOI. [Abstract]2025 Jul 4;8(1):995. PMID: 40610728 -
Respir Res
CRISPR/Cas9-mediated B2m knockout paves the way for allogeneic basal cell transplantation. [Abstract]2026 Feb 28;27(1):109. PMID: 41764471 -
-
Int J Mol Sci
2025 May 31;26(11):5306. PMID: 40508114 -
Int J Mol Sci
Role of TGF-β and p38 MAPK in TSG-6 Expression in Adipose Tissue-Derived Stem Cells In Vitro and In Vivo. [Abstract]2023 Dec 29;25(1):477. PMID: 38203646 -
Int J Cancer
TGFβ-induced EN1 promotes tumor budding of adenoid cystic carcinoma in patient-derived organoid model. [Abstract]2024 May 15;154(10):1814-1827. PMID: 38282121 -
Am J Physiol Cell Physiol
Sel1-like Proteins and Peptides are the Major Oxalobacter formigenes-derived Factors Stimulating Oxalate Transport by Human Intestinal Epithelial Cells. [Abstract]2023 Jul 1;325(1):C344-C361. PMID: 37125773 -
Mol Oncol
2024 Mar;18(3):547-561. PMID: 37872868 -
FASEB J
Alteration of cholesterol content and oxygen level in intestinal organoids after infection with Staphylococcus aureus. [Abstract]2023 Dec;37(12):e23279. PMID: 37902583 -
FASEB J
Aberrant activation of Notch1 signaling in the mouse uterine epithelium promotes hyper-proliferation by increasing estrogen sensitivity. [Abstract]2023 Jul;37(7):e22983. PMID: 37249327 -
FASEB J
Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells. [Abstract]2020 Aug;34(8):11185-11199. PMID: 32645243
A 83-01 purchased from MedChemExpress. Usage Cited in: FASEB J. 2020 Aug;34(8):11185-11199. [Abstract]
Changes in the expression of E-Cadherin (green) and Vimentin (red) are detected by immunofluorescence. TGF-β1-induced changes in the expression of protein markers during EMT were blocked after A83-01 treatment.
-
iScience
Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth. [Abstract]2026 Jan 27;29(2):114786. PMID: 41704753 -
iScience
Impact of treatment history on drug resistance of metastatic colorectal cancer organoids. [Abstract]2025 Oct 17;28(11):113801. PMID: 41280668 -
iScience
2025 Apr 3;28(5):112344. PMID: 40276762 -
iScience
Tumor-derived colorectal cancer organoids induce a unique Treg cell population by directing CD4+ T cell differentiation. [Abstract]2025 Jan 17;28(2):111827. PMID: 39995881 -
Gynecol Oncol
Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway. [Abstract]2019 Jun;153(3):639-650. PMID: 30928020
A 83-01 purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jun;153(3):639-650. [Abstract]
Analysis of E-cadherin, N-cadherin,MMP-2 and pSmad2 in SK-OV-3 and OVCAR-3 cells treated with platelets, A83-01 or their combination at protein levels (n=3). GAPDH is used as loading control.
-
Sci Rep
Comparative analysis of organoid, air-liquid interface, and direct infection models for studying pathogen-host interactions in endometrial tissue. [Abstract]2025 Mar 12;15(1):8531. PMID: 40075187 -
J Biol Chem
Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma. [Abstract]2022 Sep;298(9):102374. PMID: 35970393 -
Cell Signal
The role of FAK signaling in early placental development and trophoblast lineage specification in human pregnancy. [Abstract]2025 Jun 17:111946. PMID: 40553964 -
Front Med
Amnion-Derived Mesenchymal Stromal/Stem Cell Paracrine Signals Potentiate Human Liver Organoid Differentiation: Translational Implications for Liver Regeneration. [Abstract]2021 Sep 23;8:746298. PMID: 34631757 -
Stem Cells Int
2025 Jul 11:2025:5105796. PMID: 40689086 -
Hum Cell
Establishment and drug resistance characterization of paired organoids using human primary colorectal cancer and matched tumor deposit specimens. [Abstract]2024 Nov 4;38(1):13. PMID: 39495391 -
Biol Reprod
Evaluation of optimal trophoblastic models to mimic uterine vessel remodeling in human pregnancy†. [Abstract]2025 May 13:ioaf108. PMID: 40358012 -
Reprod Toxicol
Long-term maintenance of human endometrial epithelial organoids and their stem cell properties. [Abstract]2024 Jan:123:108522. PMID: 38096957 -
In Vitro Model
Colorectal carcinoma organoid and cancer-associated fibroblasts co-culture system for drug evaluation. [Abstract]2025 Mar 5;4(1):31-44. PMID: 40160212 -
Cancer Biomark
TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation. [Abstract]2025 Oct;42(10):18758592251390145. PMID: 41129675 -
STAR Protoc
Protocol for generating human tonsil immune organoids with epithelial and germinal center layers using low-Matrigel culture. [Abstract]2026 Feb 19;7(1):104381. PMID: 41722051 -
J Vis Exp
Two-dimensional Porcine Intestinal Organoids Reflecting the Physiological Properties of Native Gut. [Abstract]2025 Jan 31:(215). PMID: 39960208 -
-
-
-
-
-
-
-
-
-
bioRxiv
2025 Aug 8:2025.08.08.669417. PMID: 40855884 -
-
-
Methods Mol Biol
2025 May 17. PMID: 40377872 -
-
Methods Mol Biol
Generation of Human Naïve Pluripotent Stem Cell-Derived Blastoids in Thermoformed Microwell Platforms. [Abstract]2025 May 22. PMID: 40397283 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Methods Mol Biol
2024:2767:1-18. PMID: 37351840 -
-
Methods Mol Biol
Workflow for Performing Genetic Manipulation in Human Trophoblast Stem Cells Using CRISPR/Cas9 Technology. [Abstract]2024:2767:53-62. PMID: 36515893 -
Methods Mol Biol
2024:2767:43-52. PMID: 36515896 -
Methods Mol Biol
Human Pluripotent Stem Cells for High-Throughput Drug Screening and Characterization of Small Molecules. [Abstract]2022:2454:811-827. PMID: 34128205 -
溶剤 & 溶解度
DMSO : 100 mg/mL (237.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.93 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.93 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
HM-1 cells are seeded into a 96-well plate and are incubated for 18 hr. A 83-01 (1 μM) or vehicle are then added for 12 hr followed by the addition of TGF-β1 (1 ng/mL) or vehicle for 60 hr. The number of viable cells in each well is examined using the WST-1 assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Female B6C3F1 mice used for the in vivo studies are maintained under specific pathogen-free conditions. To evaluate the effect of A 83-01 on the survival of mice bearing peritoneal dissemination, HM-1 cells (1×106) are injected into the abdominal cavity via the left flank of the mouse. Starting the next day, A 83-01 (150 μg/body) or vehicles (PBS with 0.5% DMSO) are injected into the abdominal cavity three times per week. Mice are euthanized before reaching the moribund state[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (284 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Tojo M, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005 Nov;96(11):791-800. [Content Brief]
[2]. Yamamura S, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012 Jan 1;130(1):20-8. [Content Brief]
[3]. Taniguchi Y, et al. Enhanced antitumor efficacy of folate-linked liposomal Adriamycin with TGF-β type I receptor inhibitor. Cancer Sci. 2010 Oct;101(10):2207-13. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3724 mL | 11.8618 mL | 23.7237 mL | 59.3092 mL |
| 5 mM | 0.4745 mL | 2.3724 mL | 4.7447 mL | 11.8618 mL | |
| 10 mM | 0.2372 mL | 1.1862 mL | 2.3724 mL | 5.9309 mL | |
| 15 mM | 0.1582 mL | 0.7908 mL | 1.5816 mL | 3.9539 mL | |
| 20 mM | 0.1186 mL | 0.5931 mL | 1.1862 mL | 2.9655 mL | |
| 25 mM | 0.0949 mL | 0.4745 mL | 0.9489 mL | 2.3724 mL | |
| 30 mM | 0.0791 mL | 0.3954 mL | 0.7908 mL | 1.9770 mL | |
| 40 mM | 0.0593 mL | 0.2965 mL | 0.5931 mL | 1.4827 mL | |
| 50 mM | 0.0474 mL | 0.2372 mL | 0.4745 mL | 1.1862 mL | |
| 60 mM | 0.0395 mL | 0.1977 mL | 0.3954 mL | 0.9885 mL | |
| 80 mM | 0.0297 mL | 0.1483 mL | 0.2965 mL | 0.7414 mL | |
| 100 mM | 0.0237 mL | 0.1186 mL | 0.2372 mL | 0.5931 mL |
Powered by Bioz